BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6828272)

  • 1. Therapeutic effects of spironolactone in polycystic ovary syndrome.
    Milewicz A; Silber D; Kirschner MA
    Obstet Gynecol; 1983 Apr; 61(4):429-32. PubMed ID: 6828272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hirsutism--a low dose spironolactone therapy.
    Vĕtr M
    Acta Univ Palacki Olomuc Fac Med; 1989; 122():239-45. PubMed ID: 2530821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism.
    Vĕtr M; Sobek A
    Acta Univ Palacki Olomuc Fac Med; 1993; 135():55-7. PubMed ID: 7976677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of unkei-to, an herbal medicine, on endocrine function and ovulation in women with high basal levels of luteinizing hormone secretion.
    Ushiroyama T; Ikeda A; Sakai M; Hosotani T; Suzuki Y; Tsubokura S; Ueki M
    J Reprod Med; 2001 May; 46(5):451-6. PubMed ID: 11396371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antiandrogen therapy in the polycystic ovary syndrome].
    Messina M; Milani P; Gentile L; Gellona A; Monaco A; Manieri C
    Minerva Endocrinol; 1987; 12(3):231-8. PubMed ID: 3657744
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine.
    Blum I; Kaufman H; Marilus R; Rusecki Y; Chovers I
    Obstet Gynecol; 1981 May; 57(5):661-5. PubMed ID: 7219917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spironolactone for hirsutism in polycystic ovary syndrome.
    Christy NA; Franks AS; Cross LB
    Ann Pharmacother; 2005 Sep; 39(9):1517-21. PubMed ID: 16076921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of bromocryptin in polycystic ovary syndrome].
    Fuhrer J; Cheviakoff S; Rubio V
    Rev Chil Obstet Ginecol; 1989; 54(6):364-9; discussion 369-70. PubMed ID: 2485372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of Polycystic Ovaries by Estrogen Therapy.
    Gambrell RD
    Obstet Gynecol; 1976 May; 47(5):569-74. PubMed ID: 131262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.
    Evans DJ; Burke CW
    J R Soc Med; 1986 Aug; 79(8):451-3. PubMed ID: 3761287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
    Kriplani A; Agarwal N
    J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hirsutism with combined pill containing drospirenone.
    Gregoriou O; Papadias K; Konidaris S; Bakalianou K; Salakos N; Vrachnis N; Creatsas G
    Gynecol Endocrinol; 2008 Apr; 24(4):220-3. PubMed ID: 18382909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
    Song J; Shen H; Li J; Huang Z; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperprolactinaemia in polycystic ovary syndrome.
    Lunde O
    Ann Chir Gynaecol; 1981; 70(4):197-201. PubMed ID: 6797343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study.
    Karakurt F; Sahin I; Güler S; Demirbas B; Culha C; Serter R; Aral Y; Bavbek N
    Adv Ther; 2008 Apr; 25(4):321-8. PubMed ID: 18389188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.